Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BriaCell Therapeutics ( (TSE:BCT) ) has issued an announcement.
On June 16, 2025, BriaPro Therapeutics Corp., a subsidiary of BriaCell Therapeutics Corp., filed its unaudited condensed interim consolidated financial statements for the three and nine-month periods ending April 30, 2025, with Canadian securities commissions. The financial statements reveal an increase in operating losses compared to the previous year, reflecting higher research and development expenses, which may impact the company’s financial positioning and stakeholder interests.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$15.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. operates in the biotechnology industry, focusing on developing targeted immunotherapy treatments for cancer. The company is primarily engaged in advancing its proprietary immunotherapy technology to treat breast cancer, with a market focus on innovative cancer therapies.
Average Trading Volume: 16,765
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$24.58M
For detailed information about BCT stock, go to TipRanks’ Stock Analysis page.